Articles with "etavopivat 4202" as a keyword



Photo from wikipedia

Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.

Sign Up to like & get
recommendations!
Published in 2022 at "Clinical pharmacology in drug development"

DOI: 10.1002/cpdd.1058

Abstract: Etavopivat (FT-4202) is an orally administered, small-molecule allosteric activator of erythrocyte pyruvate kinase-R (PKR) in clinical development for the treatment of sickle cell disease and other hemoglobin disorders. This randomized, placebo-controlled, double-blind, first-in-human combination single-ascending… read more here.

Keywords: safety; placebo; randomized placebo; allosteric activator ... See more keywords